{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:08:30Z","timestamp":1793916510311,"version":"4.8.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Plasma biomarkers are preferable to invasive and expensive diagnostic tools, such as neuroimaging and lumbar puncture that are gold standard in the clinical management of Alzheimer\u2019s Disease (AD). Here, we investigated plasma Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NfL) and Phosphorylated-tau-181 (pTau 181) in AD and in its early stages: Subjective cognitive decline (SCD) and Mild cognitive impairment (MCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>This study included 152 patients (42 SCD, 74 MCI and 36 AD). All patients underwent comprehensive clinical and neurological assessment. Blood samples were collected for Apolipoprotein E (APOE) genotyping and plasma biomarker (GFAP, NfL, and pTau 181) measurements. Forty-three patients (7 SCD, 27 MCI, and 9 AD) underwent a follow-up (FU) visit after 2 years, and a second plasma sample was collected. Plasma biomarker levels were detected using the Simoa SR-X technology (Quanterix Corp.). Statistical analysis was performed using SPSS software version 28 (IBM SPSS Statistics). Statistical significance was set at p &amp;lt; 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      GFAP, NfL and pTau 181 levels in plasma were lower in SCD and MCI than in AD patients. In particular, plasma GFAP levels were statistically significant different between SCD and AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.003), and between MCI and AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.032). Plasma NfL was different in SCD vs MCI (\n                      <jats:italic>p<\/jats:italic>\n                      =0.026), SCD vs AD (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001), SCD vs AD FU (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;0.001), SCD FU vs AD (\n                      <jats:italic>p=0.033<\/jats:italic>\n                      ), SCD FU vs AD FU (\n                      <jats:italic>p=0.011<\/jats:italic>\n                      ), MCI vs AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.002), MCI FU vs AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.003), MCI FU vs AD FU (\n                      <jats:italic>p<\/jats:italic>\n                      =0.003) and MCI vs AD FU (\n                      <jats:italic>p<\/jats:italic>\n                      =0.003). Plasma pTau 181 concentration was significantly different between SCD and AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.001), MCI and AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.026), MCI FU and AD (\n                      <jats:italic>p<\/jats:italic>\n                      =0.020). In APOE \u03f54 carriers, a statistically significant increase in plasma NfL (\n                      <jats:italic>p&amp;lt;0.001<\/jats:italic>\n                      ) and pTau 181 levels was found (\n                      <jats:italic>p=0.014).<\/jats:italic>\n                      Moreover, an association emerged between age at disease onset and plasma GFAP (p = 0.021) and pTau181 (p &amp;lt; 0.001) levels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusions<\/jats:title>\n                    <jats:p>Plasma GFAP, NfL and pTau 181 are promising biomarkers in the diagnosis of the prodromic stages and prognosis of dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2024.1375302","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:48:11Z","timestamp":1712623691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Plasma GFAP, NfL and pTau 181 detect preclinical stages of dementia"],"prefix":"10.3389","volume":"15","author":[{"given":"Assunta","family":"Ingannato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giacomucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Sorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Nacmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and progress of hypotheses and clinical trials for Alzheimer's disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-clinpsy-032816-045136","article-title":"Subjective cognitive decline in preclinical Alzheimer's disease","volume":"13","author":"Rabin","year":"2017","journal-title":"Annu Rev Clin Psychol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2017.02.005","article-title":"Mild cognitive impairment","volume":"33","author":"Sanford","year":"2017","journal-title":"Clin Geriatr Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1021\/acschemneuro.3c00641","article-title":"Blood biomarkers in Alzheimer's disease","volume":"14","author":"Mandal","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230620","article-title":"Alzheimer\u2019s disease neuroimaging initiative. Plasma biomarkers as predictors of progression to dementia in individuals with mild cognitive impairment","volume":"98","author":"Nallapu","year":"2024","journal-title":". J Alzheimers Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032134","article-title":"Plasma markers of Alzheimer's disease pathology, neuronal injury, and astrocytic activation and MRI load of vascular pathology and neurodegeneration: the SMART-MR study","volume":"13","author":"Twait","year":"2024","journal-title":". J Am Heart Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer's disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.25.24301779","article-title":"Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer's disease","volume":"26","author":"Varma","year":"2024","journal-title":"medRxiv [Preprint]"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102044","article-title":"Biomarkers of aging in frailty and age-associated disorders: State of the art and future perspective","volume":"91","author":"Salvioli","year":"2023","journal-title":"Ageing Res Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2174\/0115672050284054240119101834","article-title":"Follow-up comparisons of two plasma biomarkers of Alzheimer's disease, neurofilament light chain, and oligomeric A\u03b2: A pilot study","author":"Shim","year":"2024","journal-title":"Curr Alzheimer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-230799","article-title":"The associations of phosphorylated tau 181 and tau 231 levels in plasma and cerebrospinal fluid with cognitive function in Alzheimer's disease: A systematic review and meta-analysis","volume":"98","author":"Li","year":"2024","journal-title":"J Alzheimers Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13195-023-01340-4","article-title":"Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease","volume":"15","author":"Yang","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12724","article-title":"Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort","volume":"19","author":"Chatterjee","year":"2023","journal-title":"Alzheimers Dement"},{"key":"B18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","article-title":"Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease","volume":"10","author":"Jessen","year":"2014","journal-title":". Alzheimers Dement"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50873","article-title":"Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse","volume":"6","author":"Alcolea","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(94)90054-x","article-title":"ApoE allele frequencies in Italian sporadic and familial Alzheimer's disease","volume":"177","author":"Sorbi","year":"1994","journal-title":"Neurosci Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11055-5","article-title":"Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment","volume":"269","author":"Giacomucci","year":"2022","journal-title":"J Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10072-023-07065-4","article-title":"The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment","volume":"45","author":"Mazzeo","year":"2023","journal-title":"Neurol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16089","article-title":"Plasma neurofilament light chain predicts Alzheimer's disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study","volume":"31","author":"Mazzeo","year":"2024","journal-title":"Eur J Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0304-3","article-title":"Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa054","article-title":"Plasma tau, neurofilament light chain and amyloid-\u03b2 levels and risk of dementia; a population-based cohort study","volume":"143","author":"de Wolf","year":"2020","journal-title":"Brain"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simr\u00e9n","year":"2022","journal-title":"Brain Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0472-5","article-title":"Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease","volume":"11","author":"Weston","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.672954","article-title":"Tracing neurological diseases in the presymptomatic phase: insights from neurofilament light chain","volume":"15","author":"Gaetani","year":"2021","journal-title":"Front Neurosci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004667","article-title":"Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration","volume":"89","author":"Weston","year":"2017","journal-title":"Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30137-X","article-title":"Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study","volume":"19","author":"Quiroz","year":"2020","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer\u2019s and Families (ALFA) study, and BioCogBank Paris Lariboisi\u00e8re cohort. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","article-title":"Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12447","article-title":"Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease","volume":"18","author":"Chatterjee","year":"2022","journal-title":"Alzheimers Dement"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics6010006","article-title":"Early dementia screening","volume":"6","author":"Panegyres","year":"2016","journal-title":"Diagnostics (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17835","article-title":"Medicare spending associated with a dementia diagnosis among older adults","volume":"70","author":"Hoffman","year":"2022","journal-title":"J Am Geriatr Soc"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","article-title":"TRAILBLAZER-ALZ 2 investigators. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":". JAMA"},{"key":"B43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000128091.92139.0f","article-title":"Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease","volume":"62","author":"Tiraboschi","year":"2004","journal-title":"Neurol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5170-04.2005","article-title":"Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model","volume":"25","author":"Fryer","year":"2005","journal-title":"J Neurosci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","article-title":"Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance","volume":"3","author":"Castellano","year":"2011","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0887-09.2009","article-title":"Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice","volume":"29","author":"Bales","year":"2009","journal-title":"J Neurosci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.151254698","article-title":"Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons","volume":"98","author":"Huang","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2003.02088.x","article-title":"Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta","volume":"87","author":"Cedazo-M\u00ednguez","year":"2003","journal-title":"J Neurochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1434398100","article-title":"Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice","volume":"100","author":"Harris","year":"2003","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1375302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:48:13Z","timestamp":1712623693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1375302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":52,"alternative-id":["10.3389\/fendo.2024.1375302"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1375302","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,9]]},"article-number":"1375302"}}